NO20060123L - Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi - Google Patents

Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi

Info

Publication number
NO20060123L
NO20060123L NO20060123A NO20060123A NO20060123L NO 20060123 L NO20060123 L NO 20060123L NO 20060123 A NO20060123 A NO 20060123A NO 20060123 A NO20060123 A NO 20060123A NO 20060123 L NO20060123 L NO 20060123L
Authority
NO
Norway
Prior art keywords
cancer
disorder
steroid hormone
uterine
type
Prior art date
Application number
NO20060123A
Other languages
English (en)
Inventor
Leena Hirvela
Nina Johansson
Pasi Koskimies
Olli Taneli Pentikainen
Tommi Nyronen
Tiina Annamaria Salminen
Mark Stuart Johnson
Pekka Lehtovuori
Original Assignee
Solvay Pharm Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv
Publication of NO20060123L publication Critical patent/NO20060123L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Joining Of Glass To Other Materials (AREA)

Abstract

Denne oppfinnelsen vedrører benzo(4,5)tieno(2,3-d)pyrimidin-4-on-forbindelser, deres 5,6-dihydro- og 5,6,7,8tetrahydroderivater, og deres anvendelse til behandlingen av en steroidhormonavhengig sykdom eller forstyrrelse, fortrinnsvis for en steroidhormonavhengig sykdom eller forstyrrelse som krever inhiberingen av et 17ß-hydroksysteroiddehydrogenaseenzym, mest foretrukket enzymet 17beta-HSD type 1, type 2 eller type 3. Den steroidhormon- avhengige sykdom eller forstyrrelse er valgt fra gruppen bestående av brystkreft, prostatakarsinom, eggstokkreft, livmorkreft, endometriumkreft og endometriumhyperplasi, endometriose, livmorfibroider, livmorleiomyom, adenomyose, dysmenoré, menoragi, metroragi, prostadyni, godartet prostatahyperplasi, prostatitt, akne, seborré, hirsutisme, androgen alopesi, for tidlig pubertet, adrenalhyperplasi, polycystisk ovariesyndrom, urinveisdysfunksjon, osteoporose, multippel sklerose, reumatoid artritt, Alzheimers sykdom, tykktarmskreft, vevssår, hudrynker og katarakter.
NO20060123A 2003-06-10 2006-01-09 Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi NO20060123L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47704703P 2003-06-10 2003-06-10
PCT/EP2004/006230 WO2005032527A2 (en) 2003-06-10 2004-06-09 Benzo (4, 5) thieno (2, 3-d) pyrimidin-4-ones and their use in therapy

Publications (1)

Publication Number Publication Date
NO20060123L true NO20060123L (no) 2006-03-09

Family

ID=34421462

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060123A NO20060123L (no) 2003-06-10 2006-01-09 Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi

Country Status (24)

Country Link
US (1) US7465739B2 (no)
EP (1) EP1635839B1 (no)
JP (1) JP4605800B2 (no)
KR (1) KR20060054189A (no)
CN (1) CN1791412A (no)
AR (1) AR044650A1 (no)
AT (1) ATE479437T1 (no)
AU (1) AU2004277311B8 (no)
BR (1) BRPI0411295A (no)
CA (1) CA2527617A1 (no)
DE (1) DE602004028934D1 (no)
DK (1) DK1635839T3 (no)
ES (2) ES2352552T3 (no)
IL (1) IL172316A0 (no)
MX (1) MXPA05012745A (no)
NO (1) NO20060123L (no)
PL (1) PL1635839T3 (no)
PT (1) PT1635839E (no)
RU (1) RU2412190C2 (no)
SA (1) SA04250159B1 (no)
SI (1) SI1635839T1 (no)
TW (1) TWI349551B (no)
WO (1) WO2005032527A2 (no)
ZA (1) ZA200508296B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7524853B2 (en) 2003-06-10 2009-04-28 Solvay Pharmaceuticals B.V. Compounds and their use in therapy
US20070232628A1 (en) * 2004-05-06 2007-10-04 Luengo Juan I Calcilytic Compounds
WO2006044826A2 (en) * 2004-10-20 2006-04-27 Compass Pharmaceuticals Llc Thiophens and their use as anti-tumor agents
CN101087793B (zh) * 2004-12-13 2011-09-07 索尔瓦药物有限公司 作为17β-羟基类固醇脱氢酶抑制剂的新的取代的噻吩嘧啶酮衍生物
FR2904000A1 (fr) * 2006-07-19 2008-01-25 Galderma Res & Dev S N C Snc Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee
FR2904318B1 (fr) * 2006-07-27 2011-02-25 Scras Derives de pyrimidinone et leur utilisation comme medicament
US8080540B2 (en) 2006-09-19 2011-12-20 Abbott Products Gmbh Therapeutically active triazoles and their use
US8288367B2 (en) 2006-11-30 2012-10-16 Solvay Pharmaceuticals Gmbh Substituted estratriene derivatives as 17BETA HSD inhibitors
DE102007015169A1 (de) 2007-03-27 2008-10-02 Universität des Saarlandes Campus Saarbrücken 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
WO2009001214A2 (en) * 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
DE102007040243A1 (de) 2007-08-25 2009-02-26 Universität des Saarlandes 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
BRPI0923126A2 (pt) * 2008-12-23 2021-09-08 President And Fellows Of Harvard College Compostos inibidores de molécula pequena de necroptose, uso e composição compreendendo os mesmos e método de diminuir necroptose
WO2012025638A1 (en) 2010-08-27 2012-03-01 Universität des Saarlandes Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2012119605A1 (en) * 2011-03-10 2012-09-13 Akar Yahya Ahmed Abdellhafeez Salem New disperse dye with potent anticancer activity
TW201520219A (zh) * 2013-03-12 2015-06-01 Lilly Co Eli 咪唑並吡啶化合物
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
CN105518017B (zh) 2013-06-25 2020-07-14 佛恩多制药有限公司 治疗活性的作为1型17β-羟基类固醇脱氢酶抑制剂的雌三烯噻唑衍生物
MX2015017879A (es) 2013-06-25 2017-03-01 Forendo Pharma Ltd Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa.
AR096728A1 (es) 2013-06-25 2016-01-27 Forendo Pharma Ltd Derivados de estratrieno-tiazol terapéuticamente activos
EP3089969A2 (en) 2014-01-03 2016-11-09 Elexopharm GmbH Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2
WO2015114663A1 (en) 2014-01-30 2015-08-06 Council Of Scientific & Industrial Research Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
GB201419102D0 (en) * 2014-10-27 2014-12-10 Imp Innovations Ltd Novel compounds
CN107207562B (zh) 2014-12-23 2020-03-06 佛恩多制药有限公司 17β-HSD1抑制剂的前药
US10413557B2 (en) 2014-12-23 2019-09-17 Forendo Pharma Ltd. Prodrugs of 17.BETA.-HSD1-inhibitors
CA3003930A1 (en) * 2015-11-04 2017-05-11 Simon Fraser University Antibiotic compounds, pharmaceutical formulations thereof and methods and uses therefor
WO2018224736A2 (en) 2017-06-08 2018-12-13 Forendo Pharma Ltd Therapeutically active steroidal derivatives
CN109503572B (zh) * 2017-09-15 2021-10-08 上海交通大学 一种合成吲哚喹啉类化合物的方法
MX2021006452A (es) 2018-12-05 2021-09-28 Forendo Pharma Ltd Compuestos estra-1,3,5(10)-trieno condensados en posición 16(17) con un anillo de pirazol como inhibidores de 17-hsd1.
KR20250003936A (ko) * 2022-04-28 2025-01-07 이난타 파마슈티칼스, 인코포레이티드 피리미디논 함유 17-베타-하이드록시스테로이드 탈수소효소 유형 13 억제제
WO2025090868A1 (en) * 2023-10-26 2025-05-01 Enanta Pharmaceuticals, Inc. Pyrimidinone-containing 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4742271B1 (no) * 1968-06-20 1972-10-25
US3775027A (en) 1971-10-01 1973-11-27 Gray Manuf Co Inc Two-speed pump
JPS62132884A (ja) 1985-12-05 1987-06-16 Mitsubishi Chem Ind Ltd ２−ベンジルチエノ〔２，３−ｄ〕ピリミジン−４（３Ｈ）−オン誘導体
EP0364598A4 (en) 1988-03-02 1992-01-15 Yoshitomi Pharmaceutical Industries, Ltd. 3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
JP3783810B2 (ja) 1997-01-14 2006-06-07 第一製薬株式会社 新規ベンゾフラノン誘導体及びその製造方法
JPH10273467A (ja) 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
JP4166433B2 (ja) 1997-09-11 2008-10-15 第一製薬株式会社 ホルモン依存性疾患治療剤
RU2000125533A (ru) * 1998-03-11 2002-10-20 Эндорешерш, Инк. (Ca) Ингибиторы 17-бета-гидроксистероиддегидрогеназ 5 и 3 типа и способы их применения
ATE355279T1 (de) 1998-08-07 2006-03-15 Novartis Vaccines & Diagnostic Pyrazole als modulatoren des östrogenrezeptors
GB9929302D0 (en) 1999-12-11 2000-02-02 Univ Cardiff Benzyl tetralins compositions and uses thereof
US6784167B2 (en) 2000-09-29 2004-08-31 Bayer Pharmaceuticals Corporation 17-beta-hydroxysteroid dehydrogenase-II inhibitors
WO2003017973A1 (en) 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. A method of treating benign gynaecological disorders and a drug delivery vehicle for use in such a method
US6903102B2 (en) 2001-09-06 2005-06-07 Schering Corporation 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US6750248B2 (en) * 2001-11-09 2004-06-15 National University Of Singapore Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof

Also Published As

Publication number Publication date
JP4605800B2 (ja) 2011-01-05
WO2005032527A2 (en) 2005-04-14
AU2004277311A1 (en) 2005-04-14
AR044650A1 (es) 2005-09-21
DK1635839T3 (da) 2011-01-03
TWI349551B (en) 2011-10-01
SA04250159B1 (ar) 2008-06-21
WO2005032527A3 (en) 2005-08-04
CN1791412A (zh) 2006-06-21
ZA200508296B (en) 2007-01-31
KR20060054189A (ko) 2006-05-22
RU2006100033A (ru) 2007-07-20
AU2004277311B8 (en) 2010-05-27
PL1635839T3 (pl) 2011-02-28
CA2527617A1 (en) 2005-04-14
ATE479437T1 (de) 2010-09-15
MXPA05012745A (es) 2006-05-17
EP1635839A2 (en) 2006-03-22
US20050038053A1 (en) 2005-02-17
TW200509937A (en) 2005-03-16
RU2412190C2 (ru) 2011-02-20
ES2352554T3 (es) 2011-02-21
ES2352552T3 (es) 2011-02-21
WO2005032527B1 (en) 2005-09-22
SI1635839T1 (sl) 2010-12-31
PT1635839E (pt) 2010-10-12
US7465739B2 (en) 2008-12-16
JP2006527226A (ja) 2006-11-30
EP1635839B1 (en) 2010-09-01
AU2004277311B2 (en) 2010-04-29
IL172316A0 (en) 2011-08-01
DE602004028934D1 (de) 2010-10-14
BRPI0411295A (pt) 2006-08-01

Similar Documents

Publication Publication Date Title
WO2005032527A3 (en) Benzo (4, 5) thieno (2, 3-d) pyrimidin-4-ones and their use in therapy
Messinger et al. New inhibitors of 17β-hydroxysteroid dehydrogenase type 1
Kang et al. Potent aromatase inhibitors and molecular mechanism of inhibitory action
WO2011082285A1 (en) Ligand-directed covalent modification of protein
ATE129013T1 (de) Steroid 5-alpha-reduktase.
PA8569501A1 (es) Compuestos utiles en terapia
TW200516079A (en) Isethionate salt of a selective CDK4 inhibitor
ATE432263T1 (de) Imidazol-4-ylmethanol-derivate zur verwendung als steroid c17-20 lyase-hemmer
CN101568547A (zh) 作为17βHSD抑制剂的被取代的雌三烯衍生物
JO2248B1 (en) Pirazolobenzodiazepines
EP2007767A1 (en) Pyrrolopyrimidine derivatives used as hsp90 inhibitors
DE60307856D1 (de) Antitumorverbindung und ihre therapeutischen verwendungen
CN107556318A (zh) 一种含哌啶的吡咯并嘧啶类化合物及其制备方法与应用
AU2002214576A1 (en) Genes related to development of refractory prostate cancer
Cui et al. Optimization of 1H-indazol-3-amine derivatives as potent fibroblast growth factor receptor inhibitors
Jo et al. Chromenylchalcones with inhibitory effects on monoamine oxidase B
Roy-Burman et al. Androgens and prostate cancer: are the descriptors valid?
TW201043633A (en) Chemical compounds 751
Lee et al. Light-induced differences in conformational dynamics of the circadian clock regulator VIVID
Mastracchio et al. Investigation of biaryl heterocycles as inhibitors of Wee1 kinase
Elfekki et al. Molecular modeling studies and synthesis of novel methyl 2-(2-(4-Oxo-3-aryl-3, 4-dihydroquinazolin-2-ylthio) acetamido) alkanoates with potential anti-cancer activity as inhibitors for methionine synthase
Indu et al. Molecular docking studies on flavonoid compounds: an insight into aromatase inhibitors
Cao et al. Microwave assisted solvent-free CH amination by silica-supported manganese dioxide
Chen et al. Novel chemosensors for detection of glutathione by reduction or substitution of naphthalimide derivatives containing sulfoxide or sulfone substituents
Couty et al. Ring expansion of 2-chloromethyl pyrrolidine or azetidine: Compared theoretical investigation

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application